Literature DB >> 16421114

Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population.

D M J van den Heuvel1, V H ten Dam, A J M de Craen, F Admiraal-Behloul, H Olofsen, E L E M Bollen, J Jolles, H M Murray, G J Blauw, R G J Westendorp, M A van Buchem.   

Abstract

OBJECTIVE: To investigate the influence of deep white matter hyperintensities (DWMH) and periventricular white matter hyperintensities (PVWMH) on progression of cognitive decline in non-demented elderly people.
METHODS: All data come from the nested MRI sub-study of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). We performed a 3 year follow up study on 554 subjects of the PROSPER study using both repeated magnetic resonance imaging and cognitive testing. Cognitive decline and its dependency on WMH severity was assessed using linear regression models adjusted for sex, age, education, treatment group, and test version when applicable.
RESULTS: We found that the volume of PVWMH at baseline was longitudinally associated with reduced mental processing speed (p = 0.0075). In addition, we found that the progression in PVWMH volume paralleled the decline in mental processing speed (p = 0.024). In contrast, neither presence nor progression of DWMH was associated with change in performance on any of the cognitive tests.
CONCLUSION: PVWMH should not be considered benign but probably underlie impairment in cognitive processing speed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421114      PMCID: PMC2077562          DOI: 10.1136/jnnp.2005.070193

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  30 in total

1.  MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study.

Authors:  R Schmidt; F Fazekas; P Kapeller; H Schmidt; H P Hartung
Journal:  Neurology       Date:  1999-07-13       Impact factor: 9.910

2.  Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study.

Authors:  J C de Groot; F E de Leeuw; M Oudkerk; J van Gijn; A Hofman; J Jolles; M M Breteler
Journal:  Ann Neurol       Date:  2000-02       Impact factor: 10.422

3.  Development of a semi-automated method for quantification of MRI gray and white matter lesions in geriatric subjects.

Authors:  Martha E Payne; Denise L Fetzer; James R MacFall; James M Provenzale; Christopher E Byrum; K Ranga R Krishnan
Journal:  Psychiatry Res       Date:  2002-08-20       Impact factor: 3.222

4.  Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements.

Authors:  P Kapeller; R Barber; R J Vermeulen; H Adèr; P Scheltens; W Freidl; O Almkvist; M Moretti; T del Ser; P Vaghfeldt; C Enzinger; F Barkhof; D Inzitari; T Erkinjunti; R Schmidt; F Fazekas
Journal:  Stroke       Date:  2003-02       Impact factor: 7.914

5.  Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk.

Authors:  P J Houx; J Shepherd; G-J Blauw; M B Murphy; I Ford; E L Bollen; B Buckley; D J Stott; W Jukema; M Hyland; A Gaw; J Norrie; A M Kamper; I J Perry; P W MacFarlane; A Edo Meinders; B J Sweeney; C J Packard; C Twomey; S M Cobbe; R G Westendorp
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

6.  Relationship between ApoE, MRI findings, and cognitive function in the Cardiovascular Health Study.

Authors:  L H Kuller; L Shemanski; T Manolio; M Haan; L Fried; N Bryan; G L Burke; R Tracy; R Bhadelia
Journal:  Stroke       Date:  1998-02       Impact factor: 7.914

7.  The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk.

Authors:  J Shepherd; G J Blauw; M B Murphy; S M Cobbe; E L Bollen; B M Buckley; I Ford; J W Jukema; M Hyland; A Gaw; A M Lagaay; I J Perry; P W Macfarlane; A E Meinders; B J Sweeney; C J Packard; R G Westendorp; C Twomey; D J Stott
Journal:  Am J Cardiol       Date:  1999-11-15       Impact factor: 2.778

8.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

Authors:  James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp
Journal:  Lancet       Date:  2002-11-23       Impact factor: 79.321

9.  Relation between age-related decline in intelligence and cerebral white-matter hyperintensities in healthy octogenarians: a longitudinal study.

Authors:  E Garde; E L Mortensen; K Krabbe; E Rostrup; H B Larsson
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

10.  Periventricular cerebral white matter lesions predict rate of cognitive decline.

Authors:  Jan Cees De Groot; Frank-Erik De Leeuw; Matthijs Oudkerk; Jan Van Gijn; Albert Hofman; Jellemer Jolles; Monique M B Breteler
Journal:  Ann Neurol       Date:  2002-09       Impact factor: 10.422

View more
  104 in total

1.  Correlations between MRI white matter lesion location and executive function and episodic memory.

Authors:  E E Smith; D H Salat; J Jeng; C R McCreary; B Fischl; J D Schmahmann; B C Dickerson; A Viswanathan; M S Albert; D Blacker; S M Greenberg
Journal:  Neurology       Date:  2011-04-26       Impact factor: 9.910

Review 2.  Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure.

Authors:  Marc R Bothe; Ingo Uttner; Markus Otto
Journal:  J Neural Transm (Vienna)       Date:  2010-01-30       Impact factor: 3.575

3.  Brain structural connectivity in late-life major depressive disorder.

Authors:  Stephen F Smagula; Howard J Aizenstein
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-05

4.  Coronary artery disease is associated with cognitive decline independent of changes on magnetic resonance imaging in cognitively normal elderly adults.

Authors:  Ling Zheng; Wendy J Mack; Helena C Chui; Lara Heflin; Dan Mungas; Bruce Reed; Charles DeCarli; Michael W Weiner; Joel H Kramer
Journal:  J Am Geriatr Soc       Date:  2012-01-27       Impact factor: 5.562

5.  Is the whole brain periventricular?

Authors:  F Barkhof; P Scheltens
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

6.  Age-related slowing of memory retrieval: contributions of perceptual speed and cerebral white matter integrity.

Authors:  Barbara Bucur; David J Madden; Julia Spaniol; James M Provenzale; Roberto Cabeza; Leonard E White; Scott A Huettel
Journal:  Neurobiol Aging       Date:  2007-03-26       Impact factor: 4.673

7.  Association of white matter hyperintensities with low serum 25-hydroxyvitamin D levels.

Authors:  J M Prager; C Thomas; W J Ankenbrandt; J R Meyer; Y Gao; A Ragin; S Sidharthan; R Hutten; Y G Wu
Journal:  AJNR Am J Neuroradiol       Date:  2014-01-16       Impact factor: 3.825

8.  Associations between cognitive and gait performance during single- and dual-task walking in people with Parkinson disease.

Authors:  Elizabeth L Stegemöller; Jonathan P Wilson; Audrey Hazamy; Mack C Shelley; Michael S Okun; Lori J P Altmann; Chris J Hass
Journal:  Phys Ther       Date:  2014-02-20

9.  Association of parental dementia with cognitive and brain MRI measures in middle-aged adults.

Authors:  S Debette; P A Wolf; A Beiser; R Au; J J Himali; A Pikula; S Auerbach; C Decarli; S Seshadri
Journal:  Neurology       Date:  2009-12-09       Impact factor: 9.910

10.  Daily functioning and prefrontal brain morphology in healthy and depressed community-dwelling elderly.

Authors:  Virginia Elderkin-Thompson; Martina Ballmaier; Gerhard Hellemann; Daniel Pham; Helen Lavretsky; Anand Kumar
Journal:  Am J Geriatr Psychiatry       Date:  2008-08       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.